Answers are grounded in this paper and cite their sources.
SUMMARy There is a general agreement that blood and blood components all deteriorate from the moment they are removed from the donor's vein. Clinicians have expressed their concern for decades about the potential of the storage lesions having adverse effects on patients. However, this has been difficult to prove in clinical studies due to the multifactorial nature and complexity of many transfusion settings, especially hemorrhagic shock and trauma. The role of transfusion as a contributor to adverse consequences that are only possible and multifactorial such as those potentially due to storage lesions can only be identified by large, well‐conducted and controlled trials. If transfusion can be identified as a significant contributory factor to a specific complication its role is considered more as a risk factor rather than a direct 1:1 causal factor. Nevertheless, it is of interest to underline that many of the changes occurring during storage are related to the presence of leukocytes (especially granulocytes) and can be minimized by pre‐storage leukoreduction. Pre‐storage leukoreduction is now standard practice in many countries. Although its introduction has been for reasons other than the minimization of storage lesions, it is of interest to note hat it is probably the most effective intervention to improve the survival and the quality of red cell and platelet concentrates.
No takes yet. Share an insight, caveat, or question.
James P. Isbister (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: